10 [67] A. L. Pozniak, J. E. Gallant, E. DeJesus et al., “Tenofovir diso- proxil fumarate, emtricitabine, and efavirenz versus ﬁxed- dose zidovudine/lamivudine and efavirenz in antiretroviral- naive patients: virologic, immunologic, and morphologic changes—a 96-week analysis,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 43, no. 5, pp. 535–540, 2006. [68] J. E. Gallant, E. Dejesus, J. R. Arribas et al., “Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV,” New England Journal of Medicine, vol. 354, no. 3, pp. 251–260, 2006. [69] F. A. Post, G. J. Moyle, H. J. Stellbrink et al., “Randomized comparison of renal eﬀects, eﬃcacy, and safety with once- daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1- infected adults: 48-week results from the ASSERT study,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 55, no. 1, pp. 49–57, 2010. [70] P. E. Sax, C. Tierney, A. C. Collier et al., “Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy,” New England Journal of Medicine, vol. 361, no. 23, pp. 2230– 2240, 2009. [71] S. Rodriguez-Nvoa, E. Alvarez, P. Labarga, and V. Soriano, “Renal toxicity associated with tenofovir use,” Expert Opinion on Drug Safety, vol. 9, no. 4, pp. 545–559, 2010. [72] C. Orkin, S. T. Sadiq, L. Rice, and F. Jackson, “Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B5701 in HIV-1-infected UK subjects,” HIV Medicine, vol. 11, no. 3, pp. 187–192, 2010. [73] L.-M. Yindom, A. Leligdowicz, M. P. Martin et al., “Inﬂuence of HLA class I and HLA-KIR compound genotypes on HIV- 2 infection and markers of disease progression in a Manjako community in West Africa,” Journal of Virology, vol. 84, no. 16, pp. 8202–8208, 2010. [74] Global Price Reporting Mechanism, 2010, http://apps.who. int/hiv/amds/price/hdd/index.aspx. [75] M. Petrella and M. A. Wainberg, “Might the M184V substitu- tion in HIV-1 RT confer clinical beneﬁt?” AIDS Reviews, vol. 4, no. 4, pp. 224–232, 2002. [76] J. K. Wakeﬁeld, S. A. Jablonski, and C. D. Morrow, “In vitro enzymatic activity of human immunodeﬁciency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome,” Journal of Virology, vol. 66, no. 11, pp. 6806–6812, 1992. [77] A. S. Alabi, S. Jaﬀar, K. Ariyoshi et al., “Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients,” AIDS, vol. 17, no. 10, pp. 1513–1520, 2003. [78] B. Rode´s, C. Toro, V. Jime´nez, and V. Soriano, “Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2,” Clinical Infectious Diseases, vol. 41, no. 2, pp. e19–e21, 2005. [79] T. de Silva, C. Van Tienen, S. Rowland-Jones, and M. Cotten, “Dual infection with HIV-1 and HIV-2: double trouble or destructive interference?” HIV Therapy, vol. 4, pp. 305–323, 2010. [80] J. D. Reeves and R. W. Doms, “Human immunodeﬁciency virus type 2,” Journal of General Virology, vol. 83, no. 6, pp. 1253–1265, 2002. [81] E. S. Daar, K. L. Kesler, C. J. Petropoulos et al., “Baseline HIV type 1 coreceptor tropism predicts disease progression,” Clinical Infectious Diseases, vol. 45, no. 5, pp. 643–649, 2007. AIDS Research and Treatment [82] S. Willey, P. J. Peters, W. M. Sullivan, P. Dorr, M. Perros, and P. R. Clapham, “Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: eﬀects of viral diversity, target cell and receptor density,” Antiviral Research, vol. 68, no. 2, pp. 96–108, 2005. [83] D. Armstrong-James, J. Stebbing, A. Scourﬁeld et al., “Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc,” Antiviral Research, vol. 86, no. 2, pp. 224–226, 2010. [84] S. M. Owen, D. Ellenberger, M. Rayﬁeld et al., “Genetically divergent strains of human immunodeﬁciency virus type 2 use multiple coreceptors for viral entry,” Journal of Virology, vol. 72, no. 7, pp. 5425–5432, 1998. [85] Y. Shi, E. Brandin, E. Vincic et al., “Evolution of human immunodeﬁciency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation,” Journal of General Virology, vol. 86, no. 12, pp. 3385–3396, 2005. [86] J. L. Lennox, E. DeJesus, D. S. Berger et al., “Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week eﬃcacy, durability, subgroup, safety, and metabolic analyses,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 55, no. 1, pp. 39–48, 2010. [87] R. T. Steigbigel, D. A. Cooper, H. Teppler et al., “Long-term eﬃcacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: week 96 results of the benchmrk 1 and 2 phase III trials,” Clinical Infectious Diseases, vol. 50, no. 4, pp. 605–612, 2010. [88] B. Roquebert, F. Damond, G. Collin et al., “HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV- 2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro,” Journal of Antimicrobial Chemotherapy, vol. 62, no. 5, pp. 914–920, 2008. [89] C. Garrido, A. M. Geretti, N. Zahonero et al., “Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection,” The Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 320–326, 2010. [90] F. Damond, S. Lariven, B. Roquebert et al., “Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients,” AIDS, vol. 22, no. 5, pp. 665–666, 2008. [91] N. Garrett, L. Xu, E. Smit, B. Ferns, S. El-Gadi, and J. Anderson, “Raltegravir treatment response in an HIV-2 infected patient: a case report,” AIDS, vol. 22, no. 9, pp. 1091– 1092, 2008. [92] M. Salgado, C. Toro, A. Sim o´n et al., “Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity,” Journal of Clinical Virology, vol. 46, no. 2, pp. 173–175, 2009. [93] M. O. C. Ota, D. O’Donovan, A. S. Alabi et al., “Maternal HIV-1 and HIV-2 infection and child survival in the Gambia,” AIDS, vol. 14, no. 4, pp. 435–439, 2000. [94] P. Lorenzi, V. M. Spicher, B. Laubereau, C. Kind, O. Irion, and L. Kaiser, “Antiretroviral therapies in pregnancy: maternal, fetal and neonatal eﬀects,” AIDS, vol. 12, no. 18, pp. F241– F247, 1998. [95] M. Mirochnick and E. Capparelli, “Pharmacokinetics of antiretrovirals in pregnant women,” Clinical Pharmacokinet- ics, vol. 43, no. 15, pp. 1071–1087, 2004. [96] J. Van Der Lugt, A. Colbers, and D. Burger, “Clinical pharmacology of HIV protease inhibitors in pregnancy,”